Li Wei, Wang Lin, Ji Xiang-Bo, Wang Li-Hong, Ge Xin, Liu Wei-Tao, Chen Ling, Zheng Zhong, Shi Zhu-Mei, Liu Ling-Zhi, Lin Marie C, Chen Jie-Yu, Jiang Bing-Hua
Department of Pathology, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.
Institute of Medical and Pharmaceutical Sciences, The Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China.
Front Oncol. 2019 Oct 15;9:1071. doi: 10.3389/fonc.2019.01071. eCollection 2019.
Glioma is the most malignant brain tumors in the world, the function and molecular mechanism of microRNA-199a (miR-199a) in glioma is not fully understood. Our research aims to investigate miR-199a/K-RAS axis in regulation of glioma tumor growth and chemoresistance. The function of miR-199a in glioma was investigated through and assays. We found that miR-199a in tumor tissues of glioma patients was significantly downregulated in this study. Kinase suppressor of ras 1 (K-RAS), was indicated as a direct target of miR-199a, as well as expression levels of K-RAS were inversely correlated with expression levels of miR-199a in human glioma specimens. Forced expression of miR-199a suppressed AKT and ERK activation, decreased HIF-1α and VEGF expression, inhibited cell proliferation and cell migration, forced expression of K-RAS restored the inhibitory effect of miR-199a on cell proliferation and cell migration. Moreover, miR-199a renders tumor cells more sensitive to temozolomide (TMZ) via targeting K-RAS. experiment validated that miR-199a functioned as a tumor suppressor, inhibited tumor growth by targeting K-RAS and suppressed activation of AKT, ERK and HIF-1α expression. Taken together, these findings indicated that miR-199a inhibits tumor growth and chemoresistance by regulating K-RAS, and the miR-199a/K-RAS axis is a potential therapeutic target for clinical intervention in glioma.
神经胶质瘤是世界上最恶性的脑肿瘤,微小RNA-199a(miR-199a)在神经胶质瘤中的功能和分子机制尚未完全明确。我们的研究旨在探究miR-199a/K-RAS轴在神经胶质瘤肿瘤生长和化疗耐药性调控中的作用。通过[具体实验方法1]和[具体实验方法2]实验研究了miR-199a在神经胶质瘤中的功能。在本研究中我们发现神经胶质瘤患者肿瘤组织中的miR-199a显著下调。Ras激酶抑制因子1(K-RAS)被证实为miR-199a的直接靶点,并且在人类神经胶质瘤标本中K-RAS的表达水平与miR-199a的表达水平呈负相关。miR-199a的过表达抑制了AKT和ERK的激活,降低了HIF-1α和VEGF的表达,抑制了细胞增殖和细胞迁移,K-RAS的过表达恢复了miR-199a对细胞增殖和细胞迁移的抑制作用。此外,miR-199a通过靶向K-RAS使肿瘤细胞对替莫唑胺(TMZ)更敏感。[具体实验名称]实验证实miR-199a发挥抑癌作用,通过靶向K-RAS抑制肿瘤生长并抑制AKT、ERK的激活以及HIF-1α的表达。综上所述,这些发现表明miR-199a通过调节K-RAS抑制肿瘤生长和化疗耐药性,并且miR-199a/K-RAS轴是神经胶质瘤临床干预的潜在治疗靶点。